The pharnacokinetic disposition of 2 g of cefoxitin administered intravenously over 30 min was determined in six patients undergoing continuous ambulatory peritoneal dialysis for chronic renal failure. During the 6-h dialysate dwell time after the drug infusion, the mean apparent volume of distribution for cefoxitin was 0.267 liter/kg (range, 0.201 to 0.325 liter/kg), and the mean elimination t1/2 from plasma was 7.8 h (range, 5.5 to 13.1 h). The peritoneal clearance, averaging 1.51 ml/min (range, 0.58 to 2.35 ml/min), was only 7.4% of the mean plasma clearance of cefoxitin. Cefoxitin clearance was reduced in patients with renal failure and was not increased by peritoneal dialysis.
Continuous ambulatory peritoneal dialysis is a self-dialysis technique used as an alternative mode of therapy in patients with end-stage renal disease. The major drawback to its use is frequent peritonitis caused by a variety of grampositive and gram-negative bacteria (6) (7) (8) . Cefoxitin, a cephamycin with broad-spectrum bactericidal activity and with a high tolerance in patients with impaired renal function (9) , is of potential use in patients who develop bacterial peritonitis. Therefore, the rate of clearance of the drug from the body during continuous ambulatory peritoneal dialysis is of importance in the designing of adequate dose schedules for these patients.
MATERIALS AND METHODS
Six patients (three males and three females) undergoing continuous ambulatory peritoneal dialysis with previously determined creatinine clearances of <10 ml/min volunteered for the study (see Table 1 ). Each subject signed the standard Montreal General Hospital consent form for participation in a clinical study. With few minor modifications, continuous ambulatory peritoneal dialysis was performed as described by others (5, 7) . Commercial dialysate solution (Baxter Laboratories) containing 1.5% dextrose was used, and each patient was studied during the 6-h dialysate dwell time of the first exchange (beginning at 0800 h) on the day of study. All patients had a physical exam, a base-line 12-channel Sequential Multiple Analyzer study, a complete blood count, erythrocyte sedimentation rate assay, and urinalysis (when possible) before being studied. Patients with hepatic disease, anemia (hemoglobin, <6 g), or a known drug allergy were excluded.
Cefoxitin (2 g) was infused intravenously over 30 min at the onset of the dialysis period in the early morning. Blood samples (5 ml) were drawn through an indwelling venous cannula kept filled with heparinized saline (1,000 U/liter). These were taken at 0, 30, 45, 60, 90, and 120 min and at 3, 4, 5, and 6 h after infusion. Urine specirnens were obtained from those three patients who were not anuric and produced urine during the study period. Blood samples and samples of urine and dialysate fluid were assayed for antimicrobial activity of cefoxitin.
The approximate concentrations of cefoxitin in the samples were first determined by a standard serial dilution tube technique. With 0.5-ml volumes of tryptone soya broth (Oxoid Ltd; CM 129), doubling dilutions of serum (or urine or peritoneal dialysate) were made in duplicate for the range of 1:2 to 1:512. Each tube was inoculated with a log-phase culture of Escherichia coli NCTC 10418 to achieve a density of 105 colony-forming units per ml. After overnight aerobic incubation at 37°C, the tubes were read turbidimetrically. The endpoints were defined as the tubes containing the lowest concentration of serum exhibiting inhibition of bacterial growth. A standard of 5 The peritoneal clearance of cefoxitin over the 6-h period after drug infusion averaged 1.44 ml/ min (range, 0.58 to 2.35 ml/min), representing a very small portion (7.4%) of the mean plasma clearance of 20.43 ml/min (range, 16.95 to 26.82 mil/min) over the same time period. In two of the three patients who produced urine, the renal clearance was 4.1 and 4.8 times larger than was the peritoneal clearance of cefoxitin.
(ii) Adverse effects. One patient complained of mild irritation lasting 1 day at the site of drug infusion. This patient had a history of gallbladder disease and developed acute biliary colic 4 h after the study began. She was in considerable distress from pain which required the administration of meperidine but was asymptomatic 8 (3) have observed a mean plasma t612 of 12 h (range, 7 to 20 h) in seven subjects with terminal renal failure, in contrast to a mean plasma tl/2 of 0.7 h in subjects with normal renal function. Patients with intermediate renal function (creatinine clearance between 12 and 62 mil/min) had plasma cefoxitin t1/2 values ranging from 1.5 to 12 h. In 10 patients with chronic renal failure (creatinine clearance, <5 ml/min), the plasma cefoxitin tl/2 averaged 10 h between dialysis sessions and 4 h during a 6-h hemodialysis session. Fillastre et al. (2) observed a plasma tl/2 of 13.2 in five patients with a creatinine clearance of <10 ml/min.
In this experiment, involving six patients with chronic renal failure (creatinine clearance, <10 ml/min), the plasma cefoxitin ti!2 averaged 7.8 h during a 6-h period of peritoneal dialysis. The relatively short sampling time necessitated by the duration of dialysis may have influenced the accuracy of our t1/2 determinations. Although we do not have plasma cefoxitin tl/2 values between dialysis sessions, as these patients were on continuous ambulatory peritoneal dialysis, clearance of cefoxitin by the peritoneal route was extremely low, averaging only 1.5 ml/min. Two 1  121  102  89  79  79  79  79  64  64   2  150  122  122  122  122  103  103  89  79   3  197  197  150  150  150  150  121  121  102  4  197  150  150  121  121  121  121  79  70   5  150  121  121  121  121  102  102  89  70   6  150  121  121  102  89  79  70  64 is unlikely that further modifications would be required for patients undergoing continuous ambulatory peritoneal dialysis. This is in contrast to the additional cefoxitin doses required after hemodialysis treatments (4).
